ClinicalTrials.gg
RecruitingNCT07573579DYNAMITE-VTUpdated Oct 8, 2026

Dynamic Voltage Mapping to Personalise the Ventricular Tachycardia Substrate

An interventional study of Dynamic Voltage Mapping and Standard of Care Ablation in Ventricular Tachycardia (VT), sponsored by Liverpool Heart and Chest Hospital NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Liverpool Heart and Chest Hospital NHS Foundation Trust · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Oct 8, 2026Now RecruitingSite recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies in Tachycardia, Ventricular with a site in United Kingdom — 12 open to participants now, 14 under way, none of them phase 3. Tachycardia, Ventricular · United Kingdom.

Planned enrollment
19th of 24
40 · median 94
Started
2026
with 1 other
No phase
23 of 38
6 open now
Primary completion
2029-03
later than 13 of 13 live
Registered
36th of 38
by date
Lead sponsor
2 of 38
Liverpool Heart and Chest Hospital NHS Foundation Trust

Among the 38 studies in Tachycardia, Ventricular with a site in United Kingdom, this one is the 19th largest by planned enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2026, is one of 23 with no phase, reaches primary completion later than 13 of the 13 other live ones, and was the 36th registered.

Tachycardia, Ventricular

452 studies on the registry are indexed under Tachycardia, Ventricular; 121 are open to participants now.

Browse Tachycardia, Ventricular studies →

Open to participants now

12 of the 38 studies in Tachycardia, Ventricular with a site in United Kingdom are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 86 Tachycardia, Ventricular studies recruiting now, 67 (78%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Tachycardia, Ventricular with a site in United Kingdom, or all of them as a file.
02

Study summary

Ventricular tachycardia (VT) is a life-threatening heart rhythm disorder and one of the commonest causes of heart-related sudden death. It often affects people who have had a heart attack or other structural heart damage. VT occurs when abnormal electrical circuits develop within and around scar tissue in the heart.

People at risk are usually offered an implantable cardiac defibrillator (ICD), a device that can detect VT and deliver a lifesaving shock. While effective, these shocks can be sudden, painful and distressing. Medications such as amiodarone can also help, but they are often unsuitable for long-term use due to their potential side effects on the liver, lungs and thyroid gland.

An alternative is catheter ablation. Thin tubes (catheters) are threaded from a blood vessel in the groin to the heart, allowing the cardiologist to identify scar tissue and abnormal electrical circuits, which can be destroyed using heat, freezing or electrical energy.

Although ablation can help many patients, VT can return in up to one in three people after the procedure. This is because it can be difficult to precisely identify the scar and surrounding tissue that sustain the abnormal circuits, making it challenging to know exactly where to apply ablation treatment.

Dynamic Voltage Mapping, is a technique which the investigators believe can more accurately identify scar and the critical bordering tissue during ablation. Initial data collected suggests that the approach accurately predicts the VT circuit and helps guide ablation.

In this study, the investigators wish to recruit 40 participants undergoing VT ablation to determine how effective Dynamic Voltage Mapping is in real-world procedures.

03

Conditions studied

  • Ventricular Tachycardia (VT)

Keywords

  • Catheter Ablation
  • Electroanatomical Mapping
  • Ventricular Tachycardia
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Scheduled for clinically indicated VT ablation (due to sustained VT episodes or ICD therapies).
  • Willing and able to give for participation in the trial
  • Male or female aged between 18-85
  • Ischaemic and non-ischaemic cardiomyopathy
  • ICD insitu

Exclusion criteria

Exclusion Criteria:

  • Unable or unwilling to consent
  • Class IV (end stage heart failure)
  • cancer
  • End stage renal disease
  • Pregnant or breast feeding
  • Severe frailty
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Dynamic Voltage Mapping Guided Ablation

    Patients assigned to this group will have Dynamic Voltage Maps available for the operator to view during the procedure to help guide ablation.

    Procedure: Dynamic Voltage Mapping

  • Active comparator
    Standard of Care Ablation

    Patients assigned to this group will receive standard of care ablation, and operators will be blinded to Dynamic Voltage Maps created during the procedure.

    Procedure: Standard of Care Ablation

Interventions

  • ProcedureDynamic Voltage Mapping

    Dynamic Voltage Mapping uses electrical information collected from catheters positioned within the heart to create an individualised map of the heart, which the investigators hypothesise will better identify scar and surrounding tissue responsible for ventricular tachycardia.

    Also known as: DVM, Dynamic Voltage Map

  • ProcedureStandard of Care Ablation

    Standard catheter ablation of ventricular tachycardia, guided by operator preference

    Also known as: Catheter ablation

06

What researchers measure

Primary outcomes

  1. Study Feasibility

    1. Proportion of screened patients who were eligible, approached, consented and recruited 2. Attrition rate: calculated as the total number of recruited patients who withdrew from the study or were lost to follow up 3. Adherence: calculated as the proportion of recruited participants who were able to fully follow the study protocol in both DVM and standard of care arms during their VT ablation procedure.

    Time frame: From enrolment to end of follow up (1 year after procedure)

Secondary outcomes

  1. Procedural Time

    Measured in minutes

    Time frame: From start of procedure to end (skin-to-skin)

  2. Ablation time/number of lesions

    Measured by number of ablation lesions applied

    Time frame: From start of procedure to end (skin-to-skin)

  3. Acute VT non-inducibility

    Ability to induce clinical VT at the end of the procedure

    Time frame: From start of procedure to end (skin-to-skin)

  4. VT recurrence Rate

    Number of sustained VT episodes/ICD shocks/therapies following procedure, recorded by implanted cardiac device

    Time frame: From end of procedure to end of follow up (12 months)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Grade Santos J, Mills MT, Calvert P, Worthington N, Phenton C, Modi S, Ashrafi R, Todd D, Waktare J, Mahida S, Gupta D, Luther V. Delineating postinfarct ventricular tachycardia substrate with dynamic voltage mapping in areas of omnipolar vector disarray. Heart Rhythm O2. 2024 Feb 27;5(4):224-233. doi: 10.1016/j.hroo.2024.02.006. eCollection 2024 Apr. PubMed 38690145 ↗
  • Khanra D, Calvert P, Hughes S, Waktare J, Modi S, Hall M, Todd D, Mahida S, Gupta D, Luther V. An approach to help differentiate postinfarct scar from borderzone tissue using Ripple Mapping during ventricular tachycardia ablation. J Cardiovasc Electrophysiol. 2023 Mar;34(3):664-672. doi: 10.1111/jce.15766. Epub 2023 Jan 12. PubMed 36478627 ↗
  • Mills MT, Calvert P, Chiong J, Gupta D, Luther V. Dynamic Voltage Mapping of the Post-infarct Ventricular Tachycardia Substrate: A Practical Technique to Help Differentiate Scar from Borderzone Tissue. Arrhythm Electrophysiol Rev. 2024 Oct 14;13:e16. doi: 10.15420/aer.2024.26. eCollection 2024. PubMed 39507206 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the results reported in publications (including baseline characteristics, procedural data, and outcome measures). Additional data may be available upon reasonable request, subject to institutional approvals and data sharing agreements.

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Time frame: IPD and supporting information will be available beginning 6 months after publication of the primary results and will remain available for 5 years thereafter.

Access criteria: De-identified individual participant data and supporting documents (study protocol, statistical analysis plan, and analytic code) will be available to qualified researchers for scientifically sound proposals. Access will be granted upon reasonable request to the study's Chief Investigator, subject to review and approval by the sponsor and in accordance with institutional and regulatory requirements. Data will be shared under a formal data sharing agreement, and access will be provided via a secure data transfer method or controlled-access environment.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Mar 2029, 30 months after the start.

Of 86 non-industry interventional studies with no phase under Tachycardia, Ventricular, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 70. This study's planned 30 months is below that.

Counting every sponsor, half of 126 studies reached it within 36 months; a quarter within 20 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2026
First posted
May 7, 2026
StartActual
Aug 3, 2026
Primary completionEst.
Mar 1, 2029
CompletionEst.
Aug 1, 2029
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 8, 2026
Sites
Liverpool Heart and Chest Hospital NHS Foundation Trust is now Recruiting
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Not yet recruiting→Recruiting
    Liverpool Heart and Chest Hospital NHS Foundation Trust is now Recruiting
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07573579
Lead sponsor
Liverpool Heart and Chest Hospital NHS Foundation Trust
Responsible party
Sponsor
First posted
May 7, 2026
Start date
Aug 3, 2026
Primary completion
Mar 1, 2029 (estimated)
Completion
Aug 1, 2029 (estimated)
Last update
Oct 8, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion